Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens

Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice

(2015) Johanna Berkhout et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Age and Sex on the Pharmacokinetics and Safety of Avibactam in Healthy Volunteers

(2015) Antoine Tarral et al.   CLINICAL THERAPEUTICS

Proliferation and significance of clinically relevant β-lactamases

(2013) Karen Bush   Annals of the New York Academy of Sciences

Efficacies of Ceftazidime-Avibactam and Ceftazidime against Pseudomonas aeruginosa in a Murine Lung Infection Model

(2013) Seth T. Housman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Pharmacodynamics of Antipseudomonal Cephalosporins in Patients with Ventilator-Associated Pneumonia

(2013) Shawn H. MacVane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

(2013) Christopher Lucasti et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

ComparativeIn VitroandIn VivoEfficacies of Human Simulated Doses of Ceftazidime and Ceftazidime-Avibactam against Pseudomonas aeruginosa

(2012) Jared L. Crandon et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study

(2012) José A. Vazquez et al.   CURRENT MEDICAL RESEARCH AND OPINION

Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy

(2012) Matteo Bassetti et al.   Expert Review of Anti-Infective Therapy

Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum  -lactamases: a systematic review and meta-analysis

(2012) K. Z. Vardakas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia

(2012) A. E. Muller et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Penetration of Meropenem into Epithelial Lining Fluid of Patients with Ventilator-Associated Pneumonia

(2011) T. P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of NXL104 in Combination with β-Lactams against Genetically Characterized Escherichia coli and Klebsiella pneumoniae Isolates Producing Class A Extended-Spectrum β-Lactamases and Class C β-Lactamases

(2011) P. R. S. Lagacé-Wiens et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activities of NXL104 Combinations with Ceftazidime and Aztreonam against Carbapenemase-ProducingEnterobacteriaceae

(2010) David M. Livermore et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hospital-Acquired Infections Due to Gram-Negative Bacteria

(2010) Anton Y. Peleg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrapulmonary Pharmacokinetics of S-013420, a Novel Bicyclolide Antibacterial, in Healthy Japanese Subjects

(2009) H. Furuie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY